Market Research Logo

Iran Pharmaceuticals and Healthcare Report Q3 2015


Attention: There is an updated edition available for this report.

BMI View: The gradual easing of sanctions in Iran will lead to an uptick in interest from multinationalpharmaceutical companies, many of which chose not to do business in Iran during this time. The supply ofhigh value patented medicines will still be satisfied by multinationals despite increasing competition fromdomestic companies, with the easing of sanctions providing a more attractive operating environment.

Headline Expenditure Projections

Pharmaceuticals: IRR60,704bn (USD2.35bn) in 2014 to IRR68,851bn (USD1.91bn) in 2015; +13.4% inlocal currency terms and -18.6% in US dollar terms. Forecast unchanged from previous quarter.

Healthcare: IRR694,087bn (USD21.83bn) in 2014 to IRR791,797bn (USD21.99bn) in 2015; +14.1% inlocal currency terms and +0.8% in US dollar terms. Forecast revised on new market data.


BMI Industry View
SWOT
Political
Economic
Operational Risk
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Iran 2011-2019)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Iran 2011-2019)
Prescription Drug Market Forecast
Patented Drug Market Forecast
Generic Drug Market Forecast
OTC Medicine Market Forecast
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Iran 2013-2019)
Table: Pharmaceutical Trade Data And Forecasts local currency (Iran 2013-2019)
Key Risks To BMI's Forecast Scenario
Macroeconomic Forecasts
Economy To Grow Again On Sanctions Relief
Table: Economic Activity (Iran 2010-2019)
Table: GDP By Expenditure (Iran 2012-2019)
Industry Risk Reward Index
Middle East And Africa Risk/Reward Index
Iran Risk/Reward Index
Rewards
Risks
Market Overview
Industry Trends And Developments
Epidemiology
Table: HIV/AIDS Prevalence In Iran
Healthcare Sector
Table: Healthcare Resources (Iran 2009-2014)
Table: Healthcare Personnel (Iran 2009-2014)
Table: Healthcare Activity (Iran 2009-2014)
Healthcare Insurance
International Healthcare Collaboration
Traditional Herbal Remedies
Research & Development
Biotechnology
Clinical Trials
Regulatory Development
Intellectual Property Regime
Counterfeit Medicines
Pricing And Reimbursement
Competitive Landscape
Pharmaceutical Sector
Generic Drugmakers
Table: Leading Drug Manufacturers, Iranian Year To March 20, 2009
Pharmaceutical Distribution
Table: Leading Distributors, Iranian Year To March 20 2008
Pharmaceutical Retail Sector
Company Profile
Amin Pharmaceutical Company
Caspian Tamin Pharmaceutical Company
Darou Pakhsh
Exir Pharmaceuticals
GlaxoSmithKline
Merck & Co
Novartis
Pars Darou
Pfizer
Pharmieco
Sanofi
Sina Darou Pharmaceutical Company
Zahravi Pharmaceutical Company
Demographic Forecast
Table: Population Headline Indicators (Iran 1990-2025)
Table: Key Population Ratios (Iran 1990-2025)
Table: Urban/Rural Population And Life Expectancy (Iran 1990-2025)
Table: Population By Age Group (Iran 1990-2025)
Table: Population By Age Group % (Iran 1990-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report